CHBV

Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis

Retrieved on: 
Tuesday, August 16, 2022
Lazarus, Immunoglobulin G, Hepatocyte, CEO, GLOBE, Blue, Growth, Leadership, Investment, HBV, IND, Board, Patient, Therapy, Infection, SAN, CHBV, Series, Hepatitis B, Institutional review board, HBsAg, Immunology, Blue jay, Disease, Pharmaceutical industry

SAN MATEO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures.

Key Points: 
  • SAN MATEO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures.
  • It will also fund development of BJT-574, an orally bioavailable small molecule HBsAg inhibitor, into first-in-human clinical trials.
  • The companys first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need.
  • The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, February 2, 2022
Therapy, CMC, University, Chicago (franchise), Immunoglobulin G, Amgen, AbbVie, Â, Adenosine, GLOBE, Hotel des Indes (The Hague), Division, NDA, Stanford University, Internal medicine, Five-prime cap, Moses Austin, Hepatitis C, CEO, Apple tree, Roche, Pediatrics, Chemistry, Cancer and Leukemia Group B, Immunology, Hepatitis B, Drug development, Technology transfer, Leukemia & Lymphoma Society, HBsAg, Leadership, Infection, Chiron Corporation, Hepatocyte, Gilead Sciences, Leukemia, SQZ, GMP, NNRTI, Hoffman, HCV, Industry, CHBV, Faculty, Patient, A2A, SAN, Bayer, Partner, HIV, Disease, Catalant, HBV, NIH, Pharmaceutical industry, Management, ImmunityBio, Searle, Blue jay, Biochemistry, Genentech

SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.

Key Points: 
  • SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.
  • Prior to Bluejay, Dr. Shulman worked at Roche, Genentech, AbbVie, and most recently at Ambys Medicines, where she was the vice president of translational medicine.
  • Prior to joining industry, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases.
  • Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.